Des-γ-Carboxyprothrombin May Be a Promising Biomarker to Determine the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma
Kazuomi Ueshima(Kindai University), Toshiharu Sakurai(Kindai University), Satoru Hagiwara(Kindai University Hospital), Hobyung Chung(Kindai University), Masahiro Takita(Kindai University), Masatoshi Kudo(Kindai University), Satoshi Kitai(Kindai University), Yasunori Minami, Tatsuo Inoue, Tomoyuki Nagai(Tohoku University), Emi Ishikawa(Kyowa Chemical Industry (Japan)), Norihisa Yada(Kindai University), Taisuke Ueda(Kindai University), Chie Tatsumi(Kindai University)
Cited by 51
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k